Research / BFI Working PaperJul 14, 2022

The Value of Pharmacy Benefit Management

In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent expiration has little effect on drug utilization especially when those drugs are delivered through insurance plans. This paper provides a quantitative model consistent with the theory and evidence in which pharmacy benefit management on behalf of insurance plans serves these and other purposes in both monopoly and oligopoly provider settings. Calibrating the model to the U.S. market, I conclude that pharmacy benefit management is worth at least $145 billion annually beyond its resource costs. PBM services add at least $192 billion annually in value to society compared to a manufacturer price-control regime. Requiring all PBM services to be self-provided by plan sponsors would forgo about 40 percent of the net value of PBM services largely by increasing management costs. Due to changes in the incidence of PBM services over the drug life cycle, the services encourage innovation even though they reduce the profits of incumbent manufacturers.

Additional Materials

More Research From These Scholars

BFI Working Paper Oct 21, 2020

An Analysis of Vice President Biden’s Economic Agenda: The Long Run Impacts of Its Regulation, Taxes, and Spending

Timothy Fitzgerald, Kevin Hassett, Cody Kallen, Casey Mulligan
Topics:  Uncategorized
BFI Working Paper Apr 22, 2021

The Backward Art of Slowing the Spread? Congregation Efficiencies during COVID-19

Casey Mulligan
Topics:  Health care, COVID-19
BFI Working Paper Dec 23, 2020

Deaths of Despair and the Incidence of Excess Mortality in 2020

Casey Mulligan
Topics:  COVID-19